Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855383 | ISIN: JP3359600008 | Ticker-Symbol: SRP
Frankfurt
05.11.24
09:17 Uhr
5,436 Euro
0,000
0,00 %
1-Jahres-Chart
SHARP CORPORATION Chart 1 Jahr
5-Tage-Chart
SHARP CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
5,5285,71819:37
5,5445,68419:34
Dow Jones News
826 Leser
Artikel bewerten:
(2)

Vaziva SA: Half-Year Results 2024 Sharp Growth And Profitability Figures

DJ VAZIVA SA: HALF-YEAR RESULTS 2024 SHARP GROWTH AND PROFITABILITY FIGURES

VAZIVA SA 
VAZIVA SA: VAZIVA SA: HALF-YEAR RESULTS 2024 SHARP GROWTH AND PROFITABILITY FIGURES 
25-Sep-2024 / 19:04 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
HALF-YEAR RESULTS 2024 
SHARP GROWTH AND PROFITABILITY FIGURES 
 
 . EBITDA: 2.3 MEUR (+130%) 
 . Operating income: 2.1 MEUR (+133%) 
 . Net income: 2.0 MEUR (+122%) 
Paris, September 25 2024 - 17h45 - Vaziva (code ISIN FR0014007T10), a pioneer in dematerialized employee benefits, 
today published its half-year results for 2024. 
 
In MEUR                                      unaudited 30.06.24 30.06.23 Variation 
SALES                                           21.3   13.7   +55,5% 
GROSS MARGIN                                        5.9   2.6   +123% 
EBITDA                                           2.3   1.0   +130% 
OPERATING INCOME                                      2.1   0.9   +133% 
NET INCOME                                         2.0   0.9   +122% In the first half of 2024, Vaziva reported solid growth in sales and operating profitability. This performance testifies to the performance of its business model and the growing adoption of its dematerialized solutions for social endowments organized by Works Councils (CSE). A fast-growing business At June 30, 2024, Vaziva posted sales of EUR21.3 million, up 55.5% on the same period in 2023. This sustained growth is the result of the increased loyalty of key account customers and the growing success of dematerialized solutions with Work Councils (CSE). Active sales development and a broader offering have enabled Vaziva to consolidate its position in the employee benefits market and become a key partner for companies' Work Councils or HR dpt. Significant rise in profitability Amid growing marketing and sales investments, Vaziva succeeded in increasing its EBITDA by 130% to EUR2.3 million, driven by the preservation of solid margins. EBITDA does not include a EUR0.7 million social security charge for an employee loyalty program in the form of a bonus share plan (AGA). After taking into account depreciation and amortization of 0.2 MEUR, operating income also showed strong growth, reaching 2.1 MEUR, up 133% on the first half of 2023. Given VAZIVA's low level of debt and favorable interest rates, financial income for the first half is negligible. After deducting income tax of around EUR0.1 million, net income came to EUR2 million, up 122%. Strengthening the financial structure At June 30, 2024, shareholders' equity stood at EUR18.68 million, up 5.6% on June 2023. Debt has been slightly reduced, with gross debt standing at EUR1.29 million compared with EUR1.44 million for the same period in 2023. Positive outlook The launch of the Spanish subsidiary, scheduled for the second half of the year, marks a key step in Vaziva's international expansion, and illustrates the company's determination to strengthen its presence in Europe. This new location will enable Vaziva to extend the reach of its dematerialized solutions and capture new markets. Meanwhile, Vaziva continues to develop innovative offerings to meet the growing needs of its key account customers. On the strength of its solid results, Vaziva is thus well positioned to pursue a path of profitable and sustainable growth in its business and earnings in 2024 and beyond. Next issue: Full-year sales 2024: Wednesday, January 29, 2025, after trading. About Vaziva Vaziva is the new-generation issuer of employee benefits (vacations, gifts, lunches) on the 1st Mastercard® multi-application smart payment card managed for Works councilss (CSE), Human Resources (HR), companies and government bodies. This card can be used on the international Mastercard® network. The Vaziva Mastercard® integrates artificial intelligence [AI] to manage social endowments according to employees' expenses and regulations in force. 
LinkedIn 
 
Instagram 
 
Twitter 
Facebook 
 CONTACTS 

VAZIVA

Christophe KOURDOULY

@ christophe.kourdouly@vaziva.com CAPVALUE Dina MORIN @ dmorin@capvalue.fr 01 80 81 50 00

-----------------------------------------------------------------------------------------------------------------------

Regulatory filing PDF file File: Press release VAZIVA_ RS 2024 250924 UK

=-------------------------------------------------------------------- 
Language:   English 
Company:   VAZIVA SA 
       31 RUE DE LA FEDERATION 
       75015 Paris 
       France 
Phone:    0672941282 
E-mail:    contact@vazivacard.com 
Internet:   www.vazivagroup.com 
ISIN:     FR0014007T10 
AMF Category: Inside information / News release on accounts, results 
EQS News ID: 1995803 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------ 

1995803 25-Sep-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1995803&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

September 25, 2024 13:04 ET (17:04 GMT)

© 2024 Dow Jones News
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.